BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Emtricitabine/tenofovir/rilpivirine regulatory update

Gilead resubmitted an NDA to FDA for a fixed-dose combination of rilpivirine and Truvada emtricitabine/tenofovir to treat HIV infection. Last month, the agency refused to file an NDA and requested additional information on the...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >